HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Edward S Kim Selected Research

lonafarnib (SCH 66336)

8/2012A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
6/2009A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
3/2008Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
8/2005Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
5/2004Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Edward S Kim Research Topics

Disease

75Neoplasms (Cancer)
06/2022 - 01/2002
57Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 07/2002
34Lung Neoplasms (Lung Cancer)
04/2021 - 07/2002
11Carcinogenesis
01/2018 - 01/2002
10Disease Progression
01/2022 - 08/2005
10Squamous Cell Carcinoma of Head and Neck
12/2019 - 05/2002
10Head and Neck Neoplasms (Head and Neck Cancer)
11/2015 - 05/2002
8Exanthema (Rash)
01/2021 - 11/2008
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 01/2003
8Mouth Neoplasms (Oral Cancer)
01/2018 - 05/2002
4Brain Neoplasms (Brain Tumor)
01/2021 - 03/2013
4Diarrhea
01/2021 - 05/2004
4Neoplasm Metastasis (Metastasis)
01/2020 - 05/2002
3Sarcoma (Soft Tissue Sarcoma)
12/2021 - 02/2012
3Fatigue
01/2021 - 12/2013
3Acne Vulgaris
01/2018 - 04/2006
3Neutropenia
04/2010 - 05/2004
3Metaplasia
02/2010 - 10/2003
2COVID-19
11/2021 - 01/2020
2Agranulocytosis (Granulocytopenia)
02/2018 - 02/2009
2Infections
02/2018 - 03/2009
2Adenocarcinoma
06/2015 - 05/2014
2Adenocarcinoma of Lung
11/2013 - 01/2013
2Colorectal Neoplasms (Colorectal Cancer)
02/2012 - 11/2010
2Hyperplasia
08/2011 - 09/2009
2Breast Neoplasms (Breast Cancer)
11/2010 - 03/2009
2Fever (Fevers)
04/2010 - 05/2004
2Leukoplakia
10/2009 - 01/2009
1Long Term Adverse Effects
06/2022
1Fibrosarcoma
06/2022

Drug/Important Bio-Agent (IBA)

23ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2003
22Biomarkers (Surrogate Marker)IBA
01/2022 - 05/2004
11Tyrosine Kinase InhibitorsIBA
06/2021 - 04/2005
10Docetaxel (Taxotere)FDA Link
02/2018 - 12/2005
10Erlotinib Hydrochloride (CP 358,774)FDA Link
02/2018 - 04/2005
9Proteins (Proteins, Gene)FDA Link
06/2022 - 05/2002
9Cetuximab (Erbitux)FDA Link
01/2018 - 02/2004
8Pharmaceutical PreparationsIBA
12/2019 - 03/2008
7PlatinumIBA
01/2021 - 11/2008
6Bevacizumab (Avastin)FDA Link
01/2022 - 04/2005
6Biological ProductsIBA
11/2021 - 01/2002
6Carboplatin (JM8)FDA LinkGeneric
01/2018 - 12/2005
6Paclitaxel (Taxol)FDA LinkGeneric
12/2013 - 05/2004
5Gefitinib (Iressa)FDA Link
12/2017 - 05/2007
5Insulin-Like PeptidesIBA
06/2015 - 05/2007
5lonafarnib (SCH 66336)IBA
08/2012 - 05/2004
4AfatinibIBA
01/2022 - 01/2017
4Monoclonal AntibodiesIBA
12/2013 - 12/2004
3Phosphotransferases (Kinase)IBA
06/2022 - 08/2012
3Immune Checkpoint InhibitorsIBA
01/2022 - 11/2020
3brigatinibIBA
05/2021 - 08/2017
3CrizotinibIBA
01/2020 - 08/2017
3LigandsIBA
01/2020 - 08/2011
3Cisplatin (Platino)FDA LinkGeneric
02/2018 - 01/2003
3DNA (Deoxyribonucleic Acid)IBA
11/2015 - 10/2004
3Insulin-Like Growth Factor I (IGF-1)IBA
05/2014 - 05/2007
3vandetanib (ZD6474)IBA
08/2012 - 01/2010
2pembrolizumabIBA
12/2021 - 04/2021
2RNA (Ribonucleic Acid)IBA
11/2021 - 08/2019
2Anaplastic Lymphoma KinaseIBA
05/2021 - 08/2017
2Messenger RNA (mRNA)IBA
06/2015 - 11/2013
2Insulin ReceptorIBA
02/2015 - 05/2012
2Insulin (Novolin)FDA Link
02/2015 - 05/2012
2Insulin-Like Growth Factor II (Somatomedin A)IBA
05/2014 - 09/2009
2Sorafenib (BAY 43-9006)FDA Link
12/2013 - 06/2011
2Pemetrexed (MTA)FDA Link
12/2013 - 12/2005
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2012 - 04/2005
2TransferasesIBA
08/2012 - 05/2002
2Antineoplastic Agents (Antineoplastics)IBA
05/2012 - 02/2004
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
08/2011 - 03/2008
2Cyclin D1IBA
08/2011 - 06/2011
2Epidermal Growth Factor (EGF)IBA
08/2011 - 01/2003
2Bexarotene (LGD1069)FDA Link
06/2011 - 06/2011
2GemcitabineFDA Link
04/2010 - 02/2009
2Taxoids (Taxanes)IBA
04/2010 - 06/2002
2Celecoxib (Celebrex)FDA Link
02/2010 - 03/2009
2IGF Type 1 Receptor (IGF 1 Receptor)IBA
09/2009 - 03/2008
2RetinoidsIBA
01/2009 - 04/2006
2SurvivinIBA
03/2008 - 10/2006
2Farnesyltranstransferase (Farnesyltransferase)IBA
08/2005 - 05/2004
2taxaneIBA
08/2005 - 05/2004
1larotrectinibIBA
06/2022
1tyrosine receptor (receptor, tyrosine)IBA
06/2022
1TropomyosinIBA
06/2022
1Circulating Tumor DNAIBA
01/2022
1atezolizumabIBA
01/2022
1Doxorubicin (Adriamycin)FDA LinkGeneric
12/2021
1Cytotoxins (Cytolysins)IBA
12/2021
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
11/2021
1Peptide Hydrolases (Proteases)FDA Link
11/2021

Therapy/Procedure

47Therapeutics
04/2022 - 01/2002
20Drug Therapy (Chemotherapy)
01/2021 - 05/2002
14Chemoprevention
01/2018 - 01/2002
5Neoadjuvant Therapy
04/2021 - 11/2010
5Radiotherapy
01/2020 - 02/2004
3Precision Medicine
01/2019 - 01/2008
2Surgical Amputation (Amputations)
06/2022 - 01/2017
2Drug Tapering
01/2020 - 03/2013
2Immunotherapy
12/2019 - 09/2018
2Combined Modality Therapy
01/2018 - 06/2004